Catherine Gagnon holds a Master’s degree in Chemistry from Université de Montréal and an MBA from UQAM. Ms. Gagnon has worked over fifteen years in the biotechnology/pharmaceutical industry, with experience in early development projects. Prior to joining Aligo, she was responsible for the corporate development activities for Angiochem where she was managing various business development and partnering activities as well as overseeing the IP activities. She has also managed the manufacturing development of various molecular classes (small molecules, peptides, proteins, radiolabel) and therapeutic areas including oncology, endocrinology, and analgesia. Prior to joining Angiochem, Catherine held progressive positions during a 7-year period at ConjuChem Biotechnologies Inc.